Anti-body Drug Approved for Classical Hodgkin Lymphoma

Adcetris is an antibody-drug conjugate, that consists of the chimeric monoclonal antibody brentuximab connected via linkers to the antimitotic (an agent that stops cell division) known as monomethyl auristatin E / MMAE. Vedotin refers to MMAE plus its linking structure. The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate, Adcetris as a first-line treatment in stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.

Related Links